Advertisement


Yasmin H. Karimi, MD, on Diffuse Large B-Cell Lymphoma: Update on Use of Epcoritamab Plus Chemotherapy

2024 ASCO Annual Meeting

Advertisement

Yasmin H. Karimi, MD, of the University of Michigan Comprehensive Cancer Center, discusses data reaffirming the efficacy and feasibility of using epcoritamab plus R-DHAX/C (rituximab, dexamethasone, cytarabine, and oxaliplatin or carboplatin) in autologous stem cell transplant–eligible patients with diffuse large B-cell lymphoma. Response rates were reported to be high, and most patients proceeded to transplant (Abstract 7032).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
For patients with relapsed refractory diffused large B-cell lymphoma salvage chemo-immunotherapy followed by consolidation with high-dose chemotherapy and autologous stem cell transplant is potentially curative, but 40 to 60% of patients can't proceed to a stem cell transplant generally due to an insufficient response to chemo-immunotherapy, and outcomes are particularly poor for patients with primary refractory disease or those with early relapse or sero rates are as low as 7%. ZUMA seven trial did show an overall survival benefit to second-line CAR T-cell; however, many patients are not candidates for CAR T or face barriers to treatment, including the distance away from a tertiary care medical center, barriers to treatment including distance away, comorbidities or rapid disease progression. And there's a need for better treatment options. Epcoritamab is a subcutaneously administered CD3, CD20 bispecific antibody and has been approved for the treatment of adults with relapsed refractory large B-cell lymphoma after two or more lines of systemic therapy and has been shown to be safe and effective in combination with standard treatments including Rituximab and chemotherapies. This is a phase two trial evaluating the combination of Epco plus R-DHAX in patients with transplant eligible, relapsed, or refractory diffused large B-cell lymphoma. The primary objective of the escalation part was the rate of dose-limiting toxicity and safety and tolerability. The primary endpoint of the expansion was overall response rate. In the expansion cohort, Epcoritamab was given until high dose chemotherapy and ontological stem cell transplant or until disease progression. As of January 2024, twenty-nine patients had received treatment. The median age was 58 and most patients had primary refractory disease or had progressed within 12 months of initial therapy. With a median follow-up time of 27.7 months, 55% of patients had proceeded to stem cell transplant. Median [inaudible 00:01:58] of dose intensity was high. Response rates were high overall, as well as in high risk subgroups with an overall response rate of 71%, and a CR rate of 63% in patients with primary refractory disease or relapse within 12 months of initial therapy. Median time to response and complete response is 1.4 and 1.5 months, respectively, in the overall population. With 27 months of median follow-up, complete responses were durable, including among high risk patients who received autologous stem cell transplant. An estimated 60% of patients including high risk patients were progression free at 24 months. All of the high risk patients who received autologous stem cell transplant all were progression free at 24 months, and Kaplan-Meier curves show that most patients, including high risk patients were alive at 24 months. Patients who proceeded to a stem cell transplant had durable remissions and five patients continued into upgraded to have monotherapy instead of transplant, two of whom had durable responses and remain on therapy beyond 30 months. The most common treatment emergent adverse events were hematologic toxicity and treatment emergent adverse events that led to R-DHAX dose modification, and discontinuation occurred in 11 and 3% of three patients, respectively. One patient had ICANN, which was grade two and resolved. Clinical tumor lysis syndrome did not occur, and there were no fatal treatment emergent adverse events. CRS was low grade occurring in 45% of patients, all grade one to two with no grade three or higher cytokine release syndrome and most commonly occurred on day 15 after the first full dose of treatment. No CRS events led to Epcoritamab discontinuation. In conclusion, with longer follow-up and new high-risk subgroup analyses, the efficacy and feasibility of Epcoritamab with R-DHAX, an auto-eligible DLBCL, support further exploration of this regimen for patients who are unable to proceed to CAR T or various to CAR T access.

Related Videos

Issues in Oncology

Andrew Srisuwananukorn, MD, and Alexander T. Pearson, MD, PhD, on Artificial Intelligence in the Clinic: Understanding How to Use This 21st Century Tool

Andrew Srisuwananukorn, MD, of The Ohio State University, and Alexander T. Pearson, MD, PhD, of the University of Chicago, discuss the use of artificial intelligence (AI) in the clinic, its potential benefits in diagnosis and treatment, resources available to help physicians learn more about AI, and what’s coming for the next generation of medical school students.

Skin Cancer

Pauline Funchain, MD and Paolo A. Ascierto, MD, on Advanced Melanoma: Results From the RELATIVITY-048 Trial

Pauline Funchain, MD, of Stanford University and the Stanford Cancer Institute, and Paolo A. Ascierto, MD, of Italy’s Istituto Nazionale Tumori and IRCCS Fondazione G. Pascale, discuss efficacy and safety findings of the triplet therapy nivolumab, relatlimab-rmbw, and ipilimumab in patients with advanced melanoma (Abstract 9504).

 

Bladder Cancer

Thomas Powles, MD, PhD, and Jonathan E. Rosenberg, MD, on Urothelial Carcinoma: The DESTINY-Pan Tumor02 Study and New Findings on Sacituzumab Govitecan

Thomas Powles, MD, PhD, of Barts Cancer Institute and the University of London, and Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, discuss clinical outcomes of sacituzumab govitecan-hziy after prior exposure to enfortumab vedotin-ejfv in patients with metastatic urothelial carcinoma, as well as the safety and efficacy of fam-trastuzumab deruxtecan-nxki in patients with HER2-expressing bladder tumors (Abstracts 4502 and 4509).

Skin Cancer

Axel Hauschild, MD, on Melanoma: Findings From the PIVOTAL Trial of Daromun vs Surgery

Axel Hauschild, MD, of Germany’s University of Kiel and University Hospital Schleswig-Holstein, discusses phase III study results on neoadjuvant intralesional daromun vs immediate surgery for patients with fully resectable, locally advanced melanoma (Abstract LBA9501).

Leukemia

Mazyar Shadman, MD, MPH, on Chronic Lymphocytic Leukemia: Recruiting for the CELESTIAL-TNCLL Study

Mazyar Shadman, MD, MPH, of Fred Hutchinson Cancer Center, discusses an ongoing phase III study of the BCL2 inhibitor sonrotoclax plus zanubrutinib vs venetoclax and obinutuzumab for patients with treatment-naive chronic lymphocytic leukemia. The investigators are recruiting internationally (see NCT06073821; Abstract TPS7087).

Advertisement

Advertisement




Advertisement